MTOR and cancer: Aspirin pretreatment disrupts the binding of the TATA-box and p300 at the initiation region of the mTOR promoter in cancer stem cells (CSCs), thereby inhibiting the binding of RNA polymerase II at these sites and suppressing mTOR gene transcription.